Skip to content
    Drishti.money
    Earnings calls

    Emcure Pharma concall ledger

    Every earnings call for EMCURE — management tone, guidance, KPIs and promise tracking, quarter by quarter.

    EMCURE · 6 transcripts · Healthcare · latest Q4 FY26
    Q4 FY26Published 05 May 2026Call held 05 May 2026

    EMCURE Q4 FY26 Earnings Call Transcript & Analysis

    FY26 Revenue₹9,204 cr+17% YoYFY26 EBITDA₹1,789 cr+22% YoYFY26 EBITDA Margin19.4%FY26 Adjusted PAT₹1,008 cr+41% YoYNet Debt₹1,054 cr

    FY26 Revenue ₹9,204 cr (+17% YoY); FY26 EBITDA ₹1,789 cr (+22% YoY); FY26 EBITDA Margin 19.4%. FY26 Revenue of ₹9,204 crores, up 16.6% YoY, surpassing $1 billion.

    Read full transcript & analysis
    Q2 FY26Published 11 Nov 2025Call held 11 Nov 2025

    EMCURE Q2 FY26 Earnings Call Transcript & Analysis

    Revenue from Operations₹2,270 cr+13% YoYEBITDA₹439 cr+15% YoYEBITDA Margin19.3%PAT₹251 cr+24% YoYGross Margin60.8%

    Revenue from Operations ₹2,270 cr (+13% YoY); EBITDA (excl. other income) ₹439 cr (+15% YoY); EBITDA Margin 19.3%. Revenue from operations grew 13.4% YoY to INR 2,270 crores.

    Read full transcript & analysis
    Q4 FY25Published 22 May 2025Call held 22 May 2025

    EMCURE Q4 FY25 Earnings Call Transcript & Analysis

    Revenue₹2,116 cr+20% YoYEBITDA₹390 cr+25% YoYEBITDA Margin18.4%PAT₹197 cr+63% YoYGross Margin57.8%

    Revenue (Q4 FY25) ₹2,116 cr (+20% YoY); EBITDA (Q4 FY25, excl. other income) ₹390 cr (+25% YoY); EBITDA Margin (Q4 FY25) 18.4%. Q4 FY25 Revenue grew 19.5% YoY to INR 2,116 crores.

    Read full transcript & analysis
    Q3 FY25Published 06 Feb 2025Call held 06 Feb 2025

    EMCURE Q3 FY25 Earnings Call Transcript & Analysis

    Revenue from Operations₹1,963 cr+18% YoYEBITDA₹362 cr+23% YoYEBITDA Margin18.4%Adjusted PAT₹171 cr+43% YoY

    Revenue from Operations ₹1,963 cr (+18% YoY); EBITDA (ex-other income) ₹362 cr (+23% YoY); EBITDA Margin 18.4%. Revenue from operations grew 18% YoY to INR 1,963 crores.

    Read full transcript & analysis